Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 8:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: atlas Clear all
Completed Not applicable Interventional

Does Echocardiographically Guided Ventriculo-Ventricular Optimization Yield a Sustained Improvement in Echocardiographic Parameters in Cardiac Resynchronization Therapy Patients? (DEVISE CRT)

NCT00737490
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure
Interventions
"Sequential Arm" (Promote , model # 2207-36 or Atlas HF , model # V-343), "Simultaneous Arm" (Promote , model # 2207-36 or Atlas HF , model # V-343)
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 1, 2014 · Synced Oct 17, 2026, 8:53 PM EDT
Terminated Phase 2 Interventional Results available

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

NCT03397394
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma, Ureter Carcinoma, Urinary Bladder Carcinoma, Urethra Carcinoma, Muscle Invasive Bladder Cancer
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
41
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 17, 2026, 8:53 PM EDT
Recruiting Phase 2 Interventional

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

NCT07175428
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
REGN7508, REGN9933, Apixaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
43
States / cities
Dothan, Alabama • Fairhope, Alabama • Covina, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors

NCT03417102
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
fitusiran, Bypassing agents
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
12 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Imaging Laterality in Chronic Stroke Patients

NCT03584425
View directory record Official record
Conditions
Stroke, Motor Cortex; Lesion
Interventions
Rasch modified version of the Fugl-Meyer Motor assessment, Anatomical image acquisition, Functional MRI task and acquisition
Diagnostic Test
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

NCT03417245
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
fitusiran, factor concentrates
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
12 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 17, 2026, 8:53 PM EDT
Completed No phase listed Observational

Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study

NCT07018401
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Pomalidomide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
San Diego, California • San Francisco, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 17, 2026, 8:53 PM EDT
Completed No phase listed Observational

Study of Tissue Samples From Patients With Non-Small Cell Lung Cancer

NCT01414595
View directory record Official record
Conditions
Lung Cancer
Interventions
DNA analysis, DNA methylation analysis, RNA analysis, gene expression analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
11
States / cities
Los Angeles, California • Lewes, Delaware • Newark, Delaware + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 17, 2026, 8:53 PM EDT
Active, not recruiting Phase 1 Interventional

The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

NCT04800692
View directory record Official record
Conditions
Claudication, Intermittent, Peripheral Artery Disease, Peripheral Vascular Diseases
Interventions
Tetrahydrobiopterin 10 mg/kg, Tetrahydrobiopterin 20 mg/kg, L-Ascorbate, L-Arginine
Drug
Lead sponsor
Louis Messina
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

ATLAS: Ambulatory Treatments for Leakage Associated With Stress

NCT00270998
View directory record Official record
Conditions
Stress Urinary Incontinence, Urinary Incontinence
Interventions
Behavioral Therapy, Intravaginal Pessary, Pessary combined with behavioral therapy
Behavioral · Device
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • Maywood, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 17, 2026, 8:53 PM EDT
Not listed Not applicable Interventional

Effects Of Osteopathic Manipulative Medicine(OMM) On Lower Extremity Muscle Characteristics In Parkinson's Disease(PD) Patients

NCT05884944
View directory record Official record
Conditions
Parkinson Disease, Osteopathy in Diseases Classified Elsewhere
Interventions
Sham- Light touch, not reaching restrictive barrier, Experimental: Interventional Group- OMM- Muscle energy
Procedure
Lead sponsor
New York Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 17, 2026, 8:53 PM EDT
Not listed Phase 4 Interventional

Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)

NCT04245436
View directory record Official record
Conditions
Anxiety, Depressive Symptoms
Interventions
Duloxetine, Escitalopram
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

NCT00257608
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
bevacizumab, placebo, erlotinib HCl
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
177
States / cities
Mobile, Alabama • Fort Smith, Arizona • Scottsdale, Arizona + 160 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 3 Interventional

TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions

NCT00371709
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
TAXUS Liberté-SR, TAXUS™ Express
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
40
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 17, 2026, 8:53 PM EDT
Active, not recruiting Not applicable Interventional

The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy

NCT03881098
View directory record Official record
Conditions
Lung Cancer
Interventions
Bronchoscopies, Sputum Sample, Venipuncture
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 17, 2026, 8:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Maximizing Visual Outcomes With Eyhance IOLs

NCT05611073
View directory record Official record
Conditions
Pseudophakia
Interventions
Visual Acuity, Biometric Data Collection, Patient Questionnaire
Diagnostic Test · Other
Lead sponsor
Berkeley Eye Center
Other
Eligibility
40 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Not applicable Interventional Results available

Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration

NCT01773954
View directory record Official record
Conditions
Age-Related Macular Degeneration, Macular Degeneration
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
MidAtlantic Retina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Cherry Hill, New Jersey • Huntingdon Valley, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 17, 2026, 8:53 PM EDT
Not listed Phase 1 Interventional

In Vivo Confocal Microscopy Tumor Atlas Study

NCT01012154
View directory record Official record
Conditions
Brain Neoplasms
Interventions
Endomicroscope
Device
Lead sponsor
Carl Zeiss Surgical GmbH
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 11, 2009 · Synced Oct 17, 2026, 8:53 PM EDT
Completed No phase listed Observational

Physiological Brain Atlas Development

NCT01210534
View directory record Official record
Conditions
Parkinson Disease, Dystonia, Tremors, Obsessive Compulsive Disorder, Depression
Interventions
No intervention
Other
Lead sponsor
Ohio State University
Other
Eligibility
7 Years to 90 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Not applicable Interventional

Treatment of Intracranial Wide-neck Aneurysms Using Stent-assisted Coil Embolization

NCT04566263
View directory record Official record
Conditions
Intracranial Aneurysms
Interventions
Neuroform EZ Stent System
Device
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 17, 2026, 8:53 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

NCT02663297
View directory record Official record
Conditions
Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Interventions
ATLCAR.CD30 cells
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
3 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2037
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Phase 2Phase 3 Interventional

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

NCT03974113
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
1 Year to 11 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Hackensack, New Jersey • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 17, 2026, 8:53 PM EDT
Completed Not applicable Interventional Results available

Neuroform Atlas Stent System Study

NCT02340585
View directory record Official record
Conditions
Intracranial Aneurysm
Interventions
Next Generation Neuroform Stent System
Device
Lead sponsor
Stryker Neurovascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
25
States / cities
Los Angeles, California • Thousand Oaks, California • Englewood, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 17, 2026, 8:53 PM EDT
Recruiting Not applicable Interventional

ATLAS (AltaValve) Pivotal Trial

NCT06465745
View directory record Official record
Conditions
Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence
Interventions
AltaValve System.
Device
Lead sponsor
4C Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 17, 2026, 8:53 PM EDT